I-VASC announces the first clinical use of VELEX™, the Empty Vein Ablation (EVA) technology device to treat Chronic Venous Insufficiency (CVI).
I-VASC, the Italy based start-up company which has developed and CE Marked its innovative percutaneous VELEX™ system to treat CVI, a condition that includes varicose veins disease, announces today that VELEX™ has entered clinical use, with the first two cases performed last week in Milan at the Policlinico San Donato center, the renowned institution of medical science.
These first two cases represent the start of the V.A.S.C. post-market clinical trial, that will be executed in a group of qualified centers, coordinated by Policlinico San Donato, that notably includes the San Raffaele Hospital in Milan and other international sites.
VELEX™ is an innovative minimally invasive catheter system which performs an advanced form of sclerotherapy (chemical ablation) based on the Empty Vein Ablation concept, invented and developed by Mario Salerno (MD), who is also the founder of I-VASC and the chairman of the board.
The EVA technology allows a fully controlled application of the sclerosant drug in the segment of vein to be treated. Before injection of the drug this segment is emptied from blood and isolated from the rest of the venous system, a solution conceived to increase both efficacy and safety of sclerotherapy through performing a simple and quick procedure.
“We are proud of having started the clinical use of VELEX™ as per our product roll-out plans” stated Daniele Zanotti, I-VASC's CEO, “and having done that at such a qualified center as San Donato, with an investigator of the experience Paolo Righini (MD) and the impressive team of Prof. Giovanni Nano. This for us, is only the first step of a market introduction path that will lead VELEX™ to be progressively introduced in the European market first, as it is already CE Marked, as well as the US market by pursuing the FDA approval too”.
Paolo Righini (MD), principal investigator of the V.A.S.C. trial, has stated “We have been following the development of this technology for a while and we were very interested in verifying its clinical performance. VELEX™ is based on a simple and elegant concept that has the potential to make endovascular chemical ablation more effective from every point of view, especially for patients with larger vessels such as the large saphenous veins treated today in this study. These veins would be the most challenging for current sclerotherapy. They would perhaps be alternatively treated with thermal/mechanical ablation, that however, require the use of anaesthesiologic drugs because of considerable intra-procedural discomfort. While only follow-up on all the approximate 30 patients to be enrolled in the study will provide sufficient data for an adequate evaluation, the procedural success and the short-term evidence give us hope for the best”.
“I am thrilled that the EVA technology has been eventually become available to CVI patients” said Mario Salerno (MD), inventor of the technology, founder of I-VASC and a vascular surgeon himself. “I have devised this concept after many years of experience with various techniques, especially sclerotherapy, that systematically fall short not only in efficacy, especially for the larger vessels to treat, but sometimes also their safety, difficulty to be used, patients’ compliance, and lastly not to mention the costs for the most recent ones. With the EVA concept I intended to strike a new level of performances that could overcome all these compromises and establish a novel therapeutic paradigm. Only the clinical use will tell us whether we have succeeded, but after the first two cases our expectation has definitely risen”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spinal Cord Stimulation Delivers Improved Arm Function30.6.2022 18:30:00 EEST | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces a Nature Neuroscience publication showing the potential for ONWARD’s ARCIM Therapy to restore movement and function in hands and arms after spinal cord injury. Regaining hand and arm function is the highest priority for many people with cervical spinal cord injury. Even mild functional deficits in hand and arm function lead to significantly reduced independence and quality of life. It has historically been challenging to develop new therapies for hand and arm function because their movements are complex and multidimensional. Researchers in today’s Nature Neuroscience publication investigated a potentially more effective approach to improving motor control of the upper limbs after spinal cord injury – an implantable neurostimulation system that modulates the spinal cord region involved in contr
NelsonHall Highlights the Strength of Mercans’ Global Employer of Record Services30.6.2022 17:00:00 EEST | Press release
“We are delighted that NelsonHall, the leading global analyst firm, has recognized Mercans as one of the fastest growing technology-driven global employer of record service providers. NelsonHall’s analyst report is a testament to the success of our EOR service line and demonstrates that our proprietary technology, combined with Mercans’ local presence in 160 countries, creates value for our customers and their employees,” said Tatjana Domovits, Group CEO of Mercans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005419/en/ Salman Saeed - Head of EOR - Mercans (Photo: AETOSWire) Mercans’ global employer of record services delivery model is unique in the industry and focuses on the excellence in customer and employee experience through digitalization, employee-centric support, and in-country expertise. Mercans has invested significantly in developing a proprietary global payroll software, HR Blizz™ with 160 country cover
IBS Intelligence Recognizes Temenos as the #1 Best-Selling Banking Software in Six Categories; the Highest Awarded to Any Technology Provider30.6.2022 16:42:00 EEST | Press release
Temenos (SIX: TEMN) has been recognized as the market's leading open platform for composable banking in the IBS Intelligence Sales League Table (SLT). IBSi recognized Temenos as the leader in six categories, more than any other technology provider, including digital banking and channels, core banking and payments. The IBSi SLT 2022 assessed systems purchases made by over 1000+ banks across 250+ products from 60 suppliers. Temenos was ranked: #1 best-selling Universal Banking - Core Banking solution with 49 new named deals, maintaining its market leadership with 49% of total deals in the market. Temenos was the only major core vendor to increase its market share year-on-year #1 for Digital Banking and Channels – signing 79 deals, maintaining more than 50% market share in the Americas #1 in Payments Systems for retail banking, for the fourth consecutive year, with 43 new named deals #1 for Risk Management with 39 new name deals, 2X the number of deals of the next vendor #1 for Islamic Co
SES Appoints Kyle Pilkington as Chief Legal Officer30.6.2022 16:15:00 EEST | Press release
SES AI Corporation (NYSE: SES), a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced the appointment of Kyle Pilkington to the position of Chief Legal Officer, effective July 1, 2022. Pilkington, who was previously VP, Legal, is based in the United States and replaces Joanne Ban on the company’s Executive Team. Ban is retiring from the position due to health reasons but will continue to serve SES as an advisor to the CEO. SES Founder & CEO, Qichao Hu said: “I am pleased to welcome Kyle to SES’s Executive Team. He brings a wealth of global experience particularly in securities laws matters and the effective oversight of legal, governance and regulatory matters and will play a key role working with me, our Board and the rest of our team as we continue to grow and strengthen the company. We also thank Joanne for all the valuable contributions over the pas
Sevan Ranked Among Top Firms on Engineering News-Record’s Lists for Fifth Consecutive Year30.6.2022 16:00:00 EEST | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) has earned spots on lists published by Engineering News-Record (ENR) for the fifth consecutive year. Sevan, a global leader in innovative program management for clients with multiple sites, was ranked No. 36 on ENR’s Top 50 Program Management Firms and No. 57 on the Top 100 Construction Management-for-Fee Firms. “Our placement on the ENR lists is a result of the extraordinary commitment our team members have to delivering excellence for our clients and business partners,” said Jim Evans, Founder and CEO of Sevan. “We are honored to be listed alongside other industry leaders on this esteemed list. Congratulations to all!” The lists recognize firms finding new momentum in their business, and rankings are based on annual revenue. ENR conducts annual surveys that assess key segments of the construction industry and ranks companies within those areas. In 2022, Sevan was recognized as an Employee-Rated Great Place to Work® for the 9th consecutive year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom